Alar Pharmaceuticals Announces First Patient Dosing in a Study of ALA-3000 (Extended-Release Ketamine Injection) for Treatment-Resistant Depression (TRD)
TAICHUNG, May 14, 2025 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage pharmaceutical company dedicated to the development of long-acting injectables to treat CNS disorders, today announced the dosing of the first patient in the multiple ascending study of subcutaneous extended-release Ketamine (ALA-3000) for Treatment-Resistant Depression (TRD) in the US. This phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose study is planning to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of ALA-3000 Injection in addition to standard of care in TRD patients.
ALA-3000, developed by Alar Pharmaceuticals, is the first formulation of ketamine lasting over one week in the blood following single dose. It has been demonstrated in the animal model for more than one month of antidepressant effects. This innovative formulation aims to alleviate symptoms of TRD by delivering a stable, low level of ketamine. By doing so, it seeks to reduce common side effects associated with rapid-acting ketamine formulations, such as sedation, dissociation, dizziness, and anxiety.
Designed with patient safety, compliance, and convenience in mind, ALA-3000 is expected to minimize the need for frequent clinic visits and prolonged on-site monitoring. This approach not only enhances the safety and durability of treatment but also aims to diminish the overall healthcare burden.
"This first-in-human clinical trial of ALA-3000 marks a significant milestone in its development." said Yung-Shun Wen Ph.D., CEO of Alar. "This represents a novel treatment pattern, where prolonged exposure to low-level ketamine may further extend its antidepressant effects, providing patients with a more stable and longer-lasting therapeutic option."
"Beyond offering patients a new treatment option, the development of ALA-3000 sustained-release injection also holds promise in mitigating the global trend of increasing off-label ketamine abuse." said Charles Lin, Founder and Chairman of Alar.
For more information, please visit Alar's website at https://alarpharm.com/ and ClinicalTrials.gov for additional information. https://clinicaltrials.gov/study/NCT06965569
View original content:https://www.prnewswire.com/news-releases/alar-pharmaceuticals-announces-first-patient-dosing-in-a-study-of-ala-3000-extended-release-ketamine-injection-for-treatment-resistant-depression-trd-302454659.html
SOURCE Alar Pharmaceuticals Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
5 hours ago
- CBS News
Michigan opioid overdose deaths expected to drop for third straight year
Opioid overdose deaths in Michigan are projected to drop in 2024, marking the third consecutive year of decline, according to the state's attorney general's office. Data from the Michigan Department of Health and Human Services shows a 34% reduction in overdose deaths between 2023 and 2024, which is around 1,000 fewer deaths, state officials said. The death rate from 2022 to 2023 decreased by 5.7% from 2,998 to 2,826. The state credits the three-year decline to investments in prevention, treatment, recovery and harm-reduction efforts, funded in part by national opioid settlements. "Since 2019, Michigan Attorney General Dana Nessel has helped secure more than $1.6 billion in settlements for Michigan governments from companies such as McKinsey & Co, Distributors Cardinal Health, McKesson, Inc., and AmerisourceBergen, Janssen Pharmaceuticals, Teva Pharmaceutical, Allergan Pharmaceutical, CVS, Walmart and Walgreens," the attorney general's office said in a news release on Thursday. In August 2024, the state projected it would see more than $1 billion from opioid settlement payments over the next 20 years or so. The attorney's office says the majority of settlement funds are distributed equally between local governments and Michigan's Opioid Healing and Recovery Fund, which was created by lawmakers in 2022 to hold funds from opioid settlements. Michigan's Opioids Task Force has distributed more than 1.3 million naloxone kits as a result of the funding, with nearly 34,000 of those kits used to reverse overdoses, the state says. In April, local organizations in Livingston County were developing proposals on how to spend around $9 million in opioid settlement funds. Learn more about the organizations working on plans in the video player above. Note: The above video first aired on April 7, 2025.
Yahoo
12 hours ago
- Yahoo
Engineering the Perfect Shower Squeegee: The Story Behind dancemoon JustHang Squeegee
NEW YORK, June 7, 2025 /PRNewswire/ -- dancemoon, the trailblazer in home cleaning innovation, proudly introduced its first-ever bathroom cleaning tool: the JustHang Squeegee. Designed for effortless use and stylish storage, the product officially launched worldwide on June 3 via dancemoon's website and Amazon, debuting at a special launch price of $19.99. It has been well-received on social media for its outstanding performance and uniquely innovative built-in hook, and has continued to gain traction on Amazon and the official website since its initial launch. What sets the JustHang Squeegee apart is the thoughtful design, inspired by the simple and universal natural habit of hanging things up after use. Through rounds of real-life testing and countless small tweaks, the dancemoon team turned this everyday habit into a clean, minimalist solution that blends form and function. And behind this seemingly simple tool is a deliberate design process worth sharing. How It's Made: Integrated Molded Structure: The built-in hook of JustHang Squeegee isn't a traditional after-assembly attachment. Instead, it is molded by one-piece injection molding. This process reduces breakage risk at joints, maintains minimalist lines and structural stability, prevents dirt buildup and avoids discoloration over time. The handle uses glass fiber reinforced PA66 and the scraper blade is made of hardened 45 steel, offering excellent strength and heat resistance, enabling JustHang Squeegee to withstand up to 75kg pressure without breaking. Size and Angle Validation: Based on user habit research, dancemoon designers analyzed common hanging points and user behaviors in the bathroom. Through multiple prototype tests and hanging simulations, the size and angle of the built-in hook were finely adjusted to ensure that it can be firmly fixed in places such as towel bars, glass doors and countertops, and perfectly fit the user's natural "use and hang" action. Premium Flexible Silicone: Made from high-elasticity 50 Shore A silicone, this material offers an ideal balance of flexibility and structural strength. After extensive durability testing, the dancemoon design team selected this specific hardness for its outstanding performance in wet and slippery environments, resisting deformation and cracking even with prolonged use. The result is a smoother, more efficient water-wiping experience and a significantly longer lifespan compared to traditional squeegees. Why JustHang Squeegee? Convenience: Effortless to hang anywhere even with wet hands. Versatility: Designed to fit seamlessly into various home settings, offering clean, clutter-free storage. Durability: One-piece molded construction minimizes breakage and lasts longer than traditional scrapers. To place an order, please visit dancemoon's Amazon store and Shopify. Or follow dancemoon on social media to stay updated with the latest campaigns for the new product: Instagram: Facebook: YouTube: About dancemoon Driven by a passion for innovative design, dancemoon infuses the beauty and emotion of the moon into each product. Beyond offering household tools, dancemoon combines innovation with minimalist design to create products that make household tasks simple and no longer a burden but an enjoyable part of life. With a vision to become the leading brand of minimalist lifestyle, dancemoon is committed to blending minimalism with household tools, bringing bliss into your daily life. CONTACT: info@ View original content to download multimedia: SOURCE dancemoon
Yahoo
21 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
